AMENDMENTS TO THE CLAIMS

CLAIMS

1. **(Currently Amended)** A method for the treatment or prophylaxis of parasitic infections, such as malaria, in man or a zoonose vector comprising the administration of an effective amount of a compound of formula I to a patient in need thereof, or to the vector~~Use of a compound according to formula I, in the manufacture of a medicament for the treatment or prophylaxis of parasitic infections in mammals, including man~~:



I

where

R^1 is H, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R^4;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C≡C-, -NR^5-;

R^4 is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C_1-C_5 alkyl, C_1-C_5 haloalkyl, C_1-C_5 alkyloxy, C_1-C_5 alkanoyl, C_1-C_5 alkanoyloxy, C_1-C_5 alkylthio, -$N(C_0$-C_3-alkyl$)_2$, hydroxymethyl, aminomethyl, carboxymethyl; -$SO_2N(C_0$-C_3-alkyl), -SO_2C_1-C_5-alkyl;

R^5 is H, C_1-C_4 alkyl, C_1-C_4 alkanoyl;

E is Si or C;

R^6, R^7 and R^8 are independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S,

R^6, R^7 and R^8 are independently optionally substituted with R^4;

G is -O-, -S-, -CHR^{10}-, -C(=O)-;

J is -CH_2-, or when G is CHR^{10} may also be -O- or -NH-;

R^{10} is H, F, -CH_3, -CH_2NH_2, -CH_2OH, -OH; or a pharmaceutically acceptable ether, amide or ester thereof

R^{11} is H, F, -CH_3, -CH_2NH_2, -CH_2OH, $CH(OH)CH_3$, $CH(NH_2)CH_3$; or a pharmaceutically acceptable ether, amide or ester thereof; or

R^{10} and R^{11} together define an olefinic bond, or together form a -CH_2-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.

2. ~~Use of a compound~~The method according to claim 1, wherein G is -O- or -CH_2-.

3. ~~Use of a compound~~The method according to claim 1 wherein R^{10} and R^{11} define an olefinic bond or a cyclopropyl group.

4. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 1, wherein R^{11} is H; CH_2OH or a pharmaceutically acceptable ether or ester thereof; or CH_2NH_2 or a pharmaceutically acceptable amide thereof.

5. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 1, wherein R^1 is H.

6. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 1, wherein D is -O- or -NH-.

7. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 6, wherein C_0-C_3-alkylene-D-C_0-C_3-alkylene is oxymethylene, oxyethylene or oxypropylene.

8. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 6, wherein C_0-C_3-alkylene-D-C_0-C_3-alkylene is aminomethylene, aminoethylene or aminopropylene.

9. **(Currently Amended)** ~~Use of a compound~~ The method according to claim 1, wherein at least two of R^6, R^7 and R^8 are aryl.

10. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 1, wherein R^6 is optionally substituted phenyl.

11. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 10 wherein R^8 is optionally substituted phenyl or pyridyl.

12. **(Currently Amended)** The method ~~Use of a compound~~ according to claim 1 wherein E is C.

13. **(Currently Amended)** The method~~Use~~ according to any preceding claim, wherein the zoonose vector is a parasite ~~is~~ and a Plasmodium species.

14. **(Currently Amended)** A compound of the formula II:



II

where

R^1 is H, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R^4;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C≡C-, -NR^5-;

R^4 is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C_1-C_5 alkyl, C_1-C_5 haloalkyl, C_1-C_5 alkyloxy, C_1-C_5 alkanoyl, C_1-C_5 alkanoyloxy, C_1-C_5 alkylthio, -N(C_0-C_3-alkyl)$_2$, hydroxymethyl, aminomethyl, carboxymethyl; -SO_2N(C_0-C_3-alkyl), -SO_2C_1-C_5-alkyl;

R^5 is H, C_1-C_4-alkyl, C_1-C_4-alkanoyl;

E is Si or C;

R^6 and R^7 are independently selected from a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S

R^8 is selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R^6, R^7 and R^8 are independently optionally substituted with R^4;

G is -O-, -S-, -CHR^{10}-, -C(=O)-;

J is -CH_2-, or when G is CHR^{10} may also be -O- or -NH-;

R^{10} is H, F, -CH_3, -CH_2NH_2, -CH_2OH, ~~-OH~~; or a pharmaceutically acceptable ether, amide or ester thereof;

R^{11} is H, F, -CH_3, -CH_2NH_2, ~~-CH_2OH,~~ CH(OH)CH_3, CH(NH_2)CH_3 or a pharmaceutically acceptable ether, amide or ester thereof; or

R^{10} and R^{11} together define an olefinic bond, or together form a -CH_2-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.

15. **(Original)** A compound according to claim 14 wherein G is -O- or -CH_2-.

16. **(Original)** A compound according to claim 14 wherein R^{10} and R^{11} define an olefinic bond or a cyclopropyl group.

17. **(Original)** A compound according to claim 14, wherein R^{11} is H; CH_2OH or a pharmaceutically acceptable ether or amide thereof, or CH_2NH_2 or a pharmaceutically acceptable amide thereof.

Rule 1.126

18. **(Original)** A compound according to claim 14, wherein R^1 is H.

19. ~~20.~~ **(Original)** A compound according to claim 14, wherein D is -O- or -NH-.

20. ~~21.~~ **(Original)** A compound according to claim 20, wherein C_0-C_3-alkylene-D-C_0-C_3-alkylene is oxymethylene, oxyethylene or oxypropylene.

21. ~~22.~~ **(Original)** A compound according to claim 20, wherein C_0-C_3-alkylene-D-C_0-C_3-alkylene is aminomethylene, aminoethylene or aminopropylene.

22. ~~23.~~ **(Original)** A compound according to claim 14, wherein R^6 is optionally substituted phenyl.

23. ~~24.~~ **(Original)** A compound according to claim 23 wherein R^8 is optionally substituted phenyl or pyridyl.

24. ~~25.~~ **(Original)** A compound according to claim 14 wherein E is C.

25. ~~26.~~ **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in ~~any preceding~~ claim 1 and a pharmaceutically acceptable carrier or diluent therefore.

26. ~~27.~~ (NEW) A compound of the formula II:



II

where

R^1 is H, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R^4;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C≡C-, -NR^5-;

R^4 is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C_1-C_5 alkyl, C_1-C_5 haloalkyl, C_1-C_5 alkyloxy, C_1-C_5 alkanoyl, C_1-C_5 alkanoyloxy, C_1-C_5 alkylthio, -$N(C_0$-C_3-alkyl$)_2$, hydroxymethyl, aminomethyl, carboxymethyl; -$SO_2N(C_0$-C_3-alkyl), -SO_2C_1-C_5-alkyl;

R^5 is H, C_1-C_4-alkyl, C_1-C_4-alkanoyl;

E is Si or C;

R^6 and R^7 are independently selected from a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S

R^8 is selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R^6, R^7 and R^8 are independently optionally substituted with R^4;

G is -S-, -CHR^{10}-, -C(=O)-;

J is -CH_2-, or when G is CHR^{10} J may also be -O- or -NH-;

R^{10} is H, F, -CH_3, -CH_2NH_2, -CH_2OH; or a pharmaceutically acceptable ether, amide or ester thereof

R^{11} is CH_2OH; or a pharmaceutically acceptable ether, amide or ester thereof; or

R^{10} and R^{11} together define an olefinic bond, or together form a -CH_2-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.